Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck u.S. Patient Assistance Program (PAP) — Patients Reached (millions)
Merck Impact Report
Latest, FY2025
0.09
Period ended Dec 31, 2025
Change on a year earlier
-7.5%
0.09 in FY2024
History
6 years
Since FY2020
Sources
1
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. Patient Assistance Program (PAP) — Patients Reached (millions) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.09 | -7.5% | – |
| FY2024 | Dec 31, 2024 | 0.09 | -27.9% | – |
| FY2023 | Dec 31, 2023 | 0.13 | +14.2% | – |
| FY2022 | Dec 31, 2022 | 0.11 | -13.1% | – |
| FY2021 | Dec 31, 2021 | 0.13 | -31.6% | – |
| FY2020 | Dec 31, 2020 | 0.19 | – | – |
Cite this data
StockData. (2026). Merck U.S. Patient Assistance Program (PAP) — Patients Reached (millions), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/esg_uspap_pat_m
See every metric in the Merck KPI table. Data updated Oct 26, 2026.